



TEXAS HEART[®] INSTITUTE

11th Annual Women's Heart & Vascular Symposium

October 2, 2021

Texas Heart Institute
Houston, Texas

Dear Participant:

On behalf of the program faculty and staff, it is my pleasure to welcome you to this symposium.

We would like to take this opportunity to thank Boston Scientific for their support.

We hope you will find that this continuing medical education activity has contributed to your medical knowledge and skills, and that you can apply this information to help improve patient outcomes. The goal is that you have a better understanding of and can improve the diagnosis, treatment and prevention of heart disease in women.

Stephanie Coulter, MD, FACC, FACE
Program Director

TABLE OF CONTENTS

CME INFORMATION

EDUCATIONAL GRANTS & EXHIBITORS

FACULTY

FACULTY LISTING

FACULTY DISCLOSURE

CME INFORMATION

Program Overview

Heart and vascular disease remain the leading contributor to morbidity and mortality among both women and men. While the decrease in mortality among women is well documented, the decline still lags behind that of men, with an alarming tendency towards an increase mortality rate among younger women.

Greater life expectancy for women, together with improvements in primary and secondary prevention of cardiovascular disease, will lead to a larger proportion of women living with disease. Substantial sex differences in the burden of different manifestations of cardiovascular disease, including coronary heart disease (CHD), stroke, heart failure, and peripheral artery disease, are widely recognized and must be addressed as new research and best practices are developed

Target Audience

The goal of this symposium is to educate all physicians caring for women today about prevention, early diagnosis and current treatment strategies for heart disease in women, including; cardiologists, cardiac surgeons, obstetricians/gynecologists, internal medicine, family practice, endocrinologists, ER attending's, nurses and nurse practitioners.

Educational Objectives

At the conclusion of this activity, the participant should be able to:

- Cite the identification of cardiac risk factors in women
- Review and clarify current guidelines for prevention, treatment and diagnosis of heart disease and stroke in women.
- Discuss and clarify cardiovascular risk stratification of female patients, which will be used to guide preventative treatment strategies.
- Discuss and implement current and new diagnostic tools and techniques.
- Discuss challenges of healthcare related to cardiovascular treatment and research in women.
- Review treatment and health promotion activities that typically require action from multiple parties, including clinicians, the broader healthcare team, and the system in which health care is delivered, as well as patients

Accreditation

Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Texas Heart Institute designates this live activity for a maximum of 7.50 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ABIM MOC Credit

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Successful completion is a passing grade of 70% on the assessment in the CME evaluation.

EDUCATIONAL GRANTS

This continuing medical education activity has been supported, in part, by the following companies:

Boston Scientific

EXHIBITORS

We thank the companies listed here for exhibiting at this symposium:

Abbott

Janssen Pulmonary Hypertension

Janssen / J&J

Novo Nordisk

FACULTY

David Aguilar, MD

Professor, University of Kentucky
Cardiologist, Gill Heart & Vascular Institute
Lexington, Kentucky

David Burkland, MD

Texas Cardiac Arrhythmia
Austin, Texas

Andrew Civitello, MD, FACC

Associate Professor
Medical Director, Heart Transplant Program
Co-Director, Advanced Heart Failure Center of Excellence
Director, Advanced Heart Failure Fellowship
Baylor St. Luke's Medical Center; Texas Heart Institute
Houston, Texas

Stephanie Coulter, MD, FACC, FASE*

Director, Texas Heart Institute Center for Women's Heart and Vascular Health
Associate Director, Non-Invasive Cardiology
Texas Heart Institute; Baylor St. Luke's Medical Center
Cardiologist, Texas Heart Medical Group
Houston, Texas

Joseph A. Diamond, MD, FACC, FAHA, FASNC

Director, Nuclear Cardiology
Department of Cardiology
Long Island Jewish Medical Center
New Hyde Park, New York

R. David Fish, MD

Director, Interventional Cardiology Research and Education
Baylor St. Luke's Medical Center; Texas Heart Institute
Interventional Cardiologist, Texas Heart Medical Group
Houston, Texas

Lauren Golden, MD

Fellow, Cardiovascular Disease Fellowship
Baylor St. Luke's Medical Center; Texas Heart Institute
Houston, Texas

Eduardo Hernandez, MD, FACC

Director, Interventional Cardiology at The Diagnostic Heart Center
Baylor St. Luke's Medical Center; Texas Heart Institute
Interventional Cardiologist, Texas Heart Medical Group
Houston, Texas

Alexander Postalian, MD

Interventional & General Cardiologist
Texas Heart Institute & Texas Heart Medical Group
Houston, Texas

Ourania Preventza, MD, FACS, MBA

Professor of Surgery, Division of Cardiothoracic Surgery
Baylor St. Luke's Medical Center
Teaching Staff, Thoracic Surgery Residency
Texas Heart Institute
Houston, Texas

Abdi Rasekh, MD

Cardiologist and Electrophysiologist
Associate Professor
Baylor College of Medicine
Teaching Staff; Texas Heart Institute Clinical Cardiac Electrophysiology Fellowship
Baylor St. Luke's Medical Center; Texas Heart Institute
Houston, Texas

Joanna Molina Razavi, MD

Associate Professor; Cardiology
Baylor College of Medicine
Teaching Staff, Cardiovascular Disease Fellowship
Teaching Staff, Clinical Cardiac Electrophysiology Fellowship
Physician Ambassador, Center for Women's Heart & Vascular Health
Texas Heart Institute
Houston, Texas

Mehdi Razavi, MD

Director, Electrophysiology Clinical Research & Innovations
Associate Professor
Baylor College of Medicine; Texas Heart Institute
Houston, Texas

Joseph G. Rogers, MD

Texas Heart Institute President and Chief Executive Officer
Cardiologist and Adjunct Professor; Division of Cardiology
Duke University
Texas Heart Institute
Cardiologist, Texas Heart Medical Group
Houston, Texas

Salim Virani, MD, PhD, FACC, FAHA

Professor of Medicine, Baylor College of Medicine
Echocardiography Laboratory, Michael E. DeBakey Veterans Affairs Medical Center
Houston, Texas

THI CME STAFF

Stephanie Jackson, MBA

CME Program Specialist
Texas Heart Institute

Elaine Allbritton

Director, CME
Texas Heart Institute

*Program Director

FACULTY DISCLOSURE STATEMENT

It is the intent of the Texas Heart Institute to assure that its educational mission and its continuing medical activities in particular, should not be influenced by the special interests of individuals associated with its program. Having an affiliation with, or an interest in, any corporate organization does not prevent a speaker from making a presentation at an educational event, but the speaker's relationship must be revealed in advance to the audience. When discussing therapeutic options, the presenter should use generic names. If it is necessary to use a trade name, then those of several companies should be used. Further, should the presentation include discussion of any unlabeled and investigational use of a commercial product, the presenter is required to disclose this to the audience.

In accordance with the guidelines of the Accreditation Council for Continuing Medical Education, everyone in a position to control content (faculty, planners, reviewers, others who control content including their spouse/partner) has disclosed to Texas Heart Institute their relevant financial relationships with commercial interests. The Institute defines "relevant financial relationships" as financial relationships of the individual (including those of the individual's spouse or partner) in any amount occurring within the past 12 months that create a conflict of interest. The ACCME defines "commercial interest" as any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients.

David Aguilar, MD has nothing to disclose relevant to this program.

David Burkland, MD has nothing to disclose relevant to this program.

Andrew Civitello, MD, FACC has nothing to disclose relevant to this program.

Stephanie Coulter, MD, FACC, FASE* has nothing to disclose relevant to this program.

Joseph A. Diamond, MD, FACC, FAHA, FASNC has nothing to disclose relevant to this program.

R. David Fish, MD is a stockholder and board member for Colibri Heart Valve, LLC.

Lauren Golden, MD has nothing to disclose relevant to this program.

Eduardo Hernandez, MD, FACC is on the speaker's bureau for Janssen Pharmaceuticals.

Alexander Postalian, MD has nothing to disclose relevant to this program.

Ourania Preventza, MD, MBA, FACS is a consultant for WL Gore & Associates & Terumo Aortic.

Abdi Rasekh, MD has nothing to disclose relevant to this program.

Joanna Molina Razavi, MD has nothing to disclose relevant to this program.

Mehdi Razavi, MD has nothing to disclose relevant to this program.

Joseph G. Rogers, MD has nothing to disclose relevant to this program.

Salim Virani, MD, PhD, FACC, FAHA has nothing to disclose relevant to this program.

The Planning Committee members have nothing to disclose.

The THI CME Staff have nothing to disclose.

The Program Reviewers have nothing to disclose.